

## IUD Quick Facts

**IUDs are a great first-line option for most patients, including those who:**

<i>Condition</i>	<i>More info</i>
<b>Have a history of ectopic pregnancy</b>	<ul style="list-style-type: none"> <li>• Can be used without restriction.<sup>1</sup></li> <li>• The absolute risk of ectopic pregnancy in IUD users is much lower than in those not using contraception, because of the IUD's effectiveness.<sup>2</sup></li> <li>• If an IUD user becomes pregnant, the pregnancy is more likely to be ectopic than a pregnancy in a non-user, but the overall rate is very low.<sup>2</sup></li> </ul>
<b>Are young and/or nulliparous</b>	<ul style="list-style-type: none"> <li>• ACOG committee opinion: IUDs should be a first-line option for nulliparous and parous adolescents.<sup>3</sup></li> <li>• Use of NSAID prior to insertion may reduce pain.<sup>4</sup></li> <li>• Routine use of miso prior to insertion is not supported by current evidence.<sup>5</sup></li> </ul>
<b>Have a history of PID</b>	<ul style="list-style-type: none"> <li>• If she had a subsequent pregnancy, no restrictions.<sup>1</sup></li> <li>• If no subsequent pregnancy, benefits thought to outweigh theoretical or proven risks (USMEC category 2) – still appropriate to use.<sup>1</sup></li> <li>• Women using IUDs are only at a higher risk of PID during the first 20 days after insertion.<sup>6</sup></li> </ul>
<b>Have a history of STI</b>	<ul style="list-style-type: none"> <li>• The concern is whether the patient may have an STI at the time of insertion,<sup>7</sup> which is associated with an increased, though still low, risk of PID.<sup>8</sup></li> <li>• It is acceptable to screen and insert on the same day,<sup>7</sup> treating with IUD in place if indicated.</li> <li>• For those who are at “increased” risk of STI, IUDs are considered category 2 or 3<sup>1</sup> – the balance between benefits and risks should be assessed on a case-by-case basis.</li> </ul>

### **IUD Medical Eligibility Resources:**

The **US Medical Eligibility for Contraceptive Use (USMEC)**, issued in 2010 and updated in 2012, is an excellent resource for assessing IUD eligibility. The full guide can be found here: <http://www.cdc.gov/reproductivehealth/unintendedpregnancy/usmec.htm>

RHEDI also offers a clinical reference sheet with this information, which can easily be printed and kept on hand: [http://rhedi.org/contraception/WHO\\_CDC\\_Chart.php](http://rhedi.org/contraception/WHO_CDC_Chart.php)

The **CDC Selected Practice Recommendations for Contraceptive Use** are an excellent resource as well:

[http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6205a1.htm?s\\_cid=rr6205a1\\_w](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6205a1.htm?s_cid=rr6205a1_w)

## IUDs can be inserted:

<i>Situation</i>	<i>More info</i>
<b>Any time in the menstrual cycle</b>	<ul style="list-style-type: none"> <li>• If it is reasonably certain the patient is not pregnant.<sup>7</sup> (Refer to the CDC Selected Practice Recommendations for details about ruling out pregnancy.)</li> <li>• Also see use of copper IUD for post-coital contraception below.</li> </ul>
<b>Immediately postpartum (including after C-section)</b>	<ul style="list-style-type: none"> <li>• An IUD can be placed within ten minutes of delivery of the placenta.<sup>1</sup></li> <li>• If it is not placed at this time, it should be inserted at least 4 weeks postpartum.<sup>1</sup></li> </ul>
<b>Immediately after a procedural abortion</b>	<ul style="list-style-type: none"> <li>• An IUD can be placed immediately following a first or second trimester suction abortion.<sup>1</sup></li> </ul>
<b>Without recent GC/C test results available</b>	<ul style="list-style-type: none"> <li>• Screening can be performed at the time of IUD insertion; insertion should not be delayed for this reason.<sup>7</sup></li> </ul>
<b>As post-coital (“emergency”) contraception (copper IUD only)</b>	<ul style="list-style-type: none"> <li>• The copper IUD is the most effective form of post-coital contraception, and is effective up to 5 days after unprotected sex.<sup>9</sup></li> </ul>

### References:

1. U S. Medical Eligibility Criteria for Contraceptive Use, 2010. Available at: [http://www.cdc.gov/mmwr/preview/mmwrhtml/rr59e0528a1.htm?s\\_cid=rr59e0528a1\\_e#box1](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr59e0528a1.htm?s_cid=rr59e0528a1_e#box1). Accessed December 19, 2013.
2. Xiong X, Buekens P, Wollast E. IUD use and the risk of ectopic pregnancy: A meta-analysis of case-control studies. *Contraception*. 1995;52(1):23–34.
3. American College of Obstetricians and Gynecologists. Committee Opinion No. 539: Adolescents and Long-Acting Reversible Contraception. 2012. Available at: [http://www.acog.org/Resources\\_And\\_Publications/Committee\\_Opinions/Committee\\_on\\_Adolescent\\_Health\\_Care/Adolescents\\_and\\_Long-Acting\\_Reversible\\_Contraception](http://www.acog.org/Resources_And_Publications/Committee_Opinions/Committee_on_Adolescent_Health_Care/Adolescents_and_Long-Acting_Reversible_Contraception).
4. Grimes DA, Hubacher D, Lopez LM, Schulz KF. Non-steroidal anti-inflammatory drugs for heavy bleeding or pain associated with intrauterine-device use. In: The Cochrane Collaboration, Grimes DA, eds. *Cochrane Database of Systematic Reviews*. Chichester, UK: John Wiley & Sons, Ltd; 2006. Available at: <http://doi.wiley.com/10.1002/14651858.CD006034.pub2>. Accessed August 22, 2013.
5. Espey E, Singh RH, Leeman L, Ogburn T, Fowler K, Greene H. Misoprostol for intrauterine device insertion in nulliparous women: a randomized controlled trial. *Am J Obstet Gynecol*. 2013. doi:10.1016/j.ajog.2013.11.018.
6. Farley TM, Rosenberg MJ, Rowe PJ, Chen JH, Meirik O. Intrauterine devices and pelvic inflammatory disease: an international perspective. *Lancet*. 1992;339(8796):785–788.
7. U.S. Selected Practice Recommendations for Contraceptive Use, 2013. Available at: <http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6205a1.htm>. Accessed July 19, 2013.
8. Mohllajee AP, Curtis KM, Peterson HB. Does insertion and use of an intrauterine device increase the risk of pelvic inflammatory disease among women with sexually transmitted infection? A systematic review. *Contraception*. 2006;73(2):145–153. doi:10.1016/j.contraception.2005.08.007.
9. Wu S, Godfrey E, Wojdyla D, et al. Copper T380A intrauterine device for emergency contraception: a prospective, multicentre, cohort clinical trial. *BJOG Int J Obstet Gynaecol*. 2010;117(10):1205–1210. doi:10.1111/j.1471-0528.2010.02652.x.